A Randomized Phase III 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab for the First-line Treatment of HER2-negative Locally Recurrent or Metastatic Breast Cancer

Trial Profile

A Randomized Phase III 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab for the First-line Treatment of HER2-negative Locally Recurrent or Metastatic Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TURANDOT
  • Most Recent Events

    • 17 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 May 2014 Planned End Date changed from 1 Nov 2013 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
    • 14 Dec 2013 Interim overall survival results in three patient cohorts presented at the 36th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top